Adimab, LLC, a provider of fully human monoclonal and multispecific antibodies, announced that it is nearing completion of adding more than 50,000 square feet to its headquarters and research campus in Lebanon, New Hampshire. Over the past seven years, Adimab has added more than 400 royalty-bearing therapeutic programs. Adimab has increased its headcount by approximately 40% over the past three years to accommodate this continual growth.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!